Cancer (Oncology)

Oncology review for 2011

Sunday 19 February 2012

Interviewee/Contributer: Bruno Pagliara

Organisation: On-Kos Pharma Consulting

Full text available to subscribers only. Click here for information on subscribing to MedNous.

How developers approach antibody drug conjugates

Saturday 12 November 2011

Interviewee/Contributer: Bruno Pagliara

Organisation: On-kòs Pharma Consulting

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Innate Pharma's anti-cancer platform attracts BMS investment

Friday 15 July 2011

Interviewee/Contributer: Herve Brailly

Organisation: Innate Pharma SA

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Vaccinating against the tumour vasculature

Monday 30 May 2011

Interviewee/Contributer: Klaus Breiner

Organisation: BB Biotech Ventures

Full text available to subscribers only. Click here for information on subscribing to MedNous.

An analysis of 2010 oncology drug failures

Sunday 10 April 2011

Interviewee/Contributer: Bruno Pagliara

Organisation: On-Kos Pharma Consulting

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Immunocore pioneers new safety studies

Monday 4 April 2011

Interviewee/Contributer: Stephen Megit

Organisation: Immunocore Ltd

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Review of oncology in 2010

Monday 14 February 2011

Interviewee/Contributer: Bruno Pagliara

Organisation: On-Kos Pharma Consulting

Full text available to subscribers only. Click here for information on subscribing to MedNous.

The peptide route to therapeutic cancer vaccines

Monday 22 November 2010

Interviewee/Contributer: Paul Higham

Organisation: Immatics Biotechnologies GmbH

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Analysis of Special Protocol Assessments for oncology

Tuesday 26 October 2010

Interviewee/Contributer: Bruno Pagliara

Organisation: On-Kòs Pharma Consulting

Full text available to subscribers only. Click here for information on subscribing to MedNous.

A good beginning in the perilous biotech business

Tuesday 26 October 2010

Interviewee/Contributer: Ingmar Hoerr

Organisation: CureVac GmbH

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Syndicate content